SPY756.10−0.49%QQQ684.00−0.92%BTC/USD73,707.10−0.30%DIA524.23−0.04%GLD365.88+0.19%TLT80.87−0.06%

Axsome Therapeutics Inc

AXSMNASDAQ

Trade with Public

$149.24

8.275.87%

Last update: Nov 11, 4:00 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Axsome Therapeutics (AXSM) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Axsome Therapeutics (AXSM) stock.

Analyst Consensus — 21 Analysts

21Buy

# Analysts21

Latest Upgrades and Downgrades for Axsome Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$284→$272
—	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$247→$249
—	UBS	Ashwani Verma	PT Cut	Buy	$256→$239
—	RBC Capital	Leonid Timashev	PT Cut	Outperform	$295→$273
—	Guggenheim	Yatin Suneja	PT Cut	Buy	$275→$250
—	Baird	Joel Beatty	PT Cut	Outperform	$246→$220
—	Piper Sandler	David Amsellem	PT Cut	Overweight	$258→$238
—	RBC Capital	Leonid Timashev	PT Cut	Outperform	$297→$295
—	Deutsche Bank	David Hoang	PT Cut	Buy	$280→$267
—	Morgan Stanley	Sean Laaman	PT Cut	Equal-Weight	$251→$247
—	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$200→$285
—	Piper Sandler	David Amsellem	Maintained	Overweight	$258
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
—	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$306→$316
—	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$242→$251
—	RBC Capital	Leonid Timashev	PT Cut	Outperform	$304→$297
—	Guggenheim	Yatin Suneja	PT Raise	Buy	$260→$275
—	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$255→$256
—	Needham	Ami Fadia	PT Raise	Buy	$267→$268
—	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$310→$306

Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) Stock Price Target 2026

Latest Upgrades and Downgrades for Axsome Therapeutics Stock

Axsome Therapeutics (AXSM) Stock Price Target 2026

Latest Upgrades and Downgrades for Axsome Therapeutics Stock

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249

PRO
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

PRO
Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

PRO
Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249

PRO
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

PRO
Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

PRO
Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) Stock Price Target 2026

Latest Upgrades and Downgrades for Axsome Therapeutics Stock

Axsome Therapeutics (AXSM) Stock Price Target 2026

Latest Upgrades and Downgrades for Axsome Therapeutics Stock

Analyst Ratings News

PROMizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272

PROMorgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249

PROUBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

PRORBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

PROGuggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

PROBaird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

People Also Watch

People Also Watch

Analyst Ratings News

PROMizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272

PROMorgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249

PROUBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

PRORBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

PROGuggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

PROBaird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249

PRO
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

PRO
Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

PRO
Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249

PRO
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

PRO
Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

PRO
Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220